Agilent Technologies, Inc. (NYSE:A) Position Reduced by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich decreased its holdings in Agilent Technologies, Inc. (NYSE:A) by 37.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 28,390 shares of the medical research company’s stock after selling 16,982 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Agilent Technologies were worth $3,947,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in Agilent Technologies in the third quarter worth approximately $25,000. MV Capital Management Inc. grew its position in Agilent Technologies by 120.7% in the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after buying an additional 105 shares during the last quarter. Baystate Wealth Management LLC grew its position in Agilent Technologies by 107.3% in the fourth quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after buying an additional 133 shares during the last quarter. Column Capital Advisors LLC grew its position in Agilent Technologies by 1,111.1% in the third quarter. Column Capital Advisors LLC now owns 327 shares of the medical research company’s stock worth $37,000 after buying an additional 300 shares during the last quarter. Finally, Rosenberg Matthew Hamilton grew its position in Agilent Technologies by 51.1% in the fourth quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after buying an additional 96 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Citigroup lifted their price target on shares of Agilent Technologies from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. Oppenheimer lifted their price objective on shares of Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. UBS Group lifted their price objective on shares of Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. Evercore ISI lifted their price objective on shares of Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Finally, Stifel Nicolaus upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $145.00 to $163.00 in a research report on Friday, April 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $141.29.

Agilent Technologies Trading Up 1.0 %

Shares of NYSE:A opened at $137.69 on Friday. The firm has a fifty day moving average of $141.59 and a two-hundred day moving average of $130.56. The firm has a market capitalization of $40.35 billion, a P/E ratio of 32.78, a price-to-earnings-growth ratio of 4.13 and a beta of 1.11. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $151.58. The company has a quick ratio of 2.04, a current ratio of 2.68 and a debt-to-equity ratio of 0.41.

Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The company had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.59 billion. During the same quarter last year, the business posted $1.37 EPS. The company’s revenue for the quarter was down 5.5% on a year-over-year basis. On average, equities analysts expect that Agilent Technologies, Inc. will post 5.5 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd were paid a $0.236 dividend. This represents a $0.94 annualized dividend and a dividend yield of 0.69%. The ex-dividend date was Monday, April 1st. Agilent Technologies’s payout ratio is presently 22.38%.

Insider Activity at Agilent Technologies

In related news, CEO Michael R. Mcmullen sold 52,297 shares of Agilent Technologies stock in a transaction on Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares of the company’s stock, valued at approximately $38,086,350. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total transaction of $239,315.72. Following the completion of the transaction, the director now owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the transaction, the chief executive officer now directly owns 253,909 shares of the company’s stock, valued at approximately $38,086,350. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,610 shares of company stock valued at $9,220,333.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.